摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Ethylsulfanyl-butylamine | 960495-26-5

中文名称
——
中文别名
——
英文名称
4-Ethylsulfanyl-butylamine
英文别名
4-ethylsulfanylbutan-1-amine
4-Ethylsulfanyl-butylamine化学式
CAS
960495-26-5
化学式
C6H15NS
mdl
——
分子量
133.258
InChiKey
YQNBIKGTDBLWLG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    8
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    51.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Synthesis and biological evaluation of sulforaphane derivatives as potential antitumor agents
    摘要:
    A series of sulforaphane derivatives were synthesized and evaluated in vitro for their cytotoxicity against five cancer cell lines (HepG2, A549, MCF-7, HCT-116 and SH-SY5Y). The pharmacological results showed that many of the derivatives displayed more potent cytotoxicity than sulforaphane (SFN). Furthermore, SFN and derivative 85 could induce cell cycle arrest at S or G2/M phase and cell apoptosis. SFN and 85 exhibited time- and dose-dependent activation on Nrf2 transcription factor, and 85 acted as a more potent Nrf2 inducer than SFN. (C) 2013 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2013.03.045
  • 作为产物:
    描述:
    2-(4-(ethylthio)butyl)isoindoline-1,3-dione 在 一水合肼 作用下, 以 甲醇 为溶剂, 生成 4-Ethylsulfanyl-butylamine
    参考文献:
    名称:
    Synthesis and biological evaluation of sulforaphane derivatives as potential antitumor agents
    摘要:
    A series of sulforaphane derivatives were synthesized and evaluated in vitro for their cytotoxicity against five cancer cell lines (HepG2, A549, MCF-7, HCT-116 and SH-SY5Y). The pharmacological results showed that many of the derivatives displayed more potent cytotoxicity than sulforaphane (SFN). Furthermore, SFN and derivative 85 could induce cell cycle arrest at S or G2/M phase and cell apoptosis. SFN and 85 exhibited time- and dose-dependent activation on Nrf2 transcription factor, and 85 acted as a more potent Nrf2 inducer than SFN. (C) 2013 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2013.03.045
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2261213A1
    公开(公告)日:2010-12-15
    The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种具有黑色素浓集激素受体拮抗作用和低毒性的化合物,可用作预防或治疗肥胖等疾病的药剂。本发明涉及一种由下式(I)表示的化合物:其中每个符号如规范中定义的,或其盐。
  • Carbamates of rapamycin
    申请人:Wyeth
    公开号:EP1266900A1
    公开(公告)日:2002-12-18
    The invention concerns a compound of the structure wherein R1 and R2 are each, independently, hydrogen, -CONH-[(CR3R4)m(-A-(CR5R6)n)p]q-B; R3, R4, R5, R6, R9 and R10 are each defined substitutents, and R3-6 may each also represent hydrogen, B is alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkylthioalkyl of 2-12 carbon atoms, alkylaminoalkyl of 2-12 carbon atoms, dialkylaminoalkyl of 3-12 carbon atoms, -OR7, -SR7, -CN, -COR7, -CONHR7, -OSO3R7, -NR7R8, -NHCOR7, -NHSO2R7, or Ar; A is -CH2-, -NR7-, -O-, -S-, -SO-, -PR7-, -NHCO-, -NHSO- or -P(O)(R7)-; Ar is naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, indolyl, thiazolyl, isoxazolyl, pyrimidinyl, pyrazinyl, imidazolyl, benzopyranyl, benz[b]thiophenolyl, benzimidazolyl, benzthiazolyl, benzodioxolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuranyl, or pyrrolidinyl; wherein the Ar group may be optionally mono-, di-, or tri- substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, hydroxy, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, dialkylaminoalkyl of 3-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkylthio of 1-6 carbon atoms, -SO3H -PO3H, and -CO2H; PO3H, and -CO2H; is a nitrogen containing heterocycle that may be saturated, unsaturated, or partially unsaturated, and may be optionally mono-, di-, or tri- substituted with a defined substituent, with the proviso that R1 and R2 are not both hydrogen; m=0-6; n=0-6; p=0-1; q=0-1; or a pharmaceutically acceptable salt thereof which is useful as an immunosuppressive, antiinflammatory, antifungal, antiproliferative, and antitumor agent.
    该发明涉及一种具有以下结构的化合物,其中R1和R2分别独立地为氢,-CONH-[(CR3R4)m(-A-(CR5R6)n)p]q-B;R3、R4、R5、R6、R9和R10均为定义的取代基,R3-6也可以分别表示氢,B为2-7个碳原子的烯基,2-7个碳原子的炔基,1-6个碳原子的羟基烷基,2-12个碳原子的烷硫基烷基,2-12个碳原子的烷基氨基烷基,3-12个碳原子的二烷基氨基烷基,-OR7,-SR7,-CN,-COR7,-CONHR7,-OSO3R7,-NR7R8,-NHCOR7,-NHSO2R7或Ar;A为-CH2-,-NR7-,-O-,-S-,-SO-,-PR7-,-NHCO-,-NHSO-或-P(O)(R7)-;Ar为萘基,吡啶基,喹啉基,异喹啉基,喹啉基,噻吩基,噻萘基,呋喃基,苯并呋喃基,苯二氧基基,苯氧唑基,苯并异唑基,吲哚基,噻唑基,异噁唑基,嘧啶基,吡啉基,咪唑基,苯并吡喃基,苯并噻吩基,苯并咪唑基,苯并噻唑基,苯二氧唑基,哌啶基,吗啉基,哌嗪基,四氢呋喃基或吡咯烷基;其中Ar基可以选择性地单取代、双取代或三取代,取代基可选自1-6个碳原子的烷基,7-10个碳原子的芳基烷基,1-6个碳原子的烷氧基,氰基,卤素,羟基,硝基,2-7个碳原子的羰基烷氧基,三氟甲基,氨基,1-6个碳原子的二烷基氨基,3-12个碳原子的二烷基氨基烷基,1-6个碳原子的羟基烷基,2-12个碳原子的烷氧基烷基,1-6个碳原子的烷硫基,-SO3H,-PO3H和-CO2H;PO3H和-CO2H;是一种含氮杂环,可以饱和、不饱和或部分不饱和,并且可以选择性地单取代、双取代或三取代具有定义的取代基,但R1和R2不能同时为氢;m=0-6;n=0-6;p=0-1;q=0-1;或其药学上可接受的盐,可用作免疫抑制剂、抗炎剂、抗真菌剂、抗增殖剂和抗肿瘤剂。
  • TRMT2A INHIBITORS FOR USE IN THE TREATMENT OF POLYGLUTAMINE DISEASES
    申请人:Forschungszentrum Jülich GmbH/ Abteilung RP-PT
    公开号:EP3659593A1
    公开(公告)日:2020-06-03
    The present invention relates to inhibitors of the enzyme TRMT2A and medical uses thereof. More particularly, the present invention relates to the treatment and the prevention of polyglutamine diseases using TRMT2A inhibitors.
    本发明涉及 TRMT2A 酶的抑制剂及其医疗用途。更具体地说,本发明涉及使用 TRMT2A 抑制剂治疗和预防多聚谷氨酰胺疾病。
  • US5302584A
    申请人:——
    公开号:US5302584A
    公开(公告)日:1994-04-12
  • US5411967A
    申请人:——
    公开号:US5411967A
    公开(公告)日:1995-05-02
查看更多